Immunic Will Develop IMU-856, Promising IBD Therapy

Immunic Will Develop IMU-856, Promising IBD Therapy
Immunic earned the exclusive rights to develop a group of innovative disease-modifying therapies, now renamed IMU-856, for inflammatory bowel disease (IBD). IMU-856, originally developed by Daiichi Sankyo, is an oral small molecule whose target is yet undisclosed but is a key player in the onset and relapse of both forms of IBD, ulcerative colitis and Crohn’s disease. “We are very excited that Daiichi Sankyo selected the Immunic team as their partner to take over the future development of this unique drug candidate,” Daniel Vitt, CEO of Immunic, said in a press release. “During the last two years, we reviewed multiple therapeutic products in the field of IBD and we are convinced that the disease-modifying concept of IMU-856 offers outstanding new therapeutic potential for patients suffering from ulcerative colitis and Crohn’s disease,” Vitt said. The therapy’s mode of action is not immune-modulatory, meaning that the immune system’s surveillance is maintained. “This product offers unique potentially disease-modifying properties and will act in a way that is very different from all currently available therapies. Most therapies for IBD patients act by unintentionally decreasing the body’s immune surveillance, resulting in higher risks regarding, for example, infections or malignant tumors,” said Andreas Mühler, MD, chief medical officer at Immunic AG. Daiichi Sankyo identified IMU-856 after a systematic screening and selectivity assessment for its target and structure. Moreover, IMU-856 was validated in genetic studies and in animal models of IBD. IMU-856 is currently undergoing preclinical testing and its first-in-human Phase 1 trial with healthy volunteers is expected to begin in the near future. Daiichi Sankyo has decided
Subscribe or to access all post and page content.